Bio-Path Holdings Company Profile (NASDAQ:BPTH)

About Bio-Path Holdings (NASDAQ:BPTH)

Bio-Path Holdings logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BPTH
  • CUSIP: N/A
  • Web: www.biopathholdings.com
Capitalization:
  • Market Cap: $38.02 million
  • Outstanding Shares: 100,056,000
Average Prices:
  • 50 Day Moving Avg: $0.31
  • 200 Day Moving Avg: $0.49
  • 52 Week Range: $0.25 - $1.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.14
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $13,000.00
  • Price / Sales: 2,655.33
  • Book Value: $0.09 per share
  • Price / Book: 3.92
Profitability:
  • EBIDTA: ($8,690,000.00)
  • Return on Equity: -56.53%
  • Return on Assets: -43.24%
Debt:
  • Current Ratio: 13.65%
  • Quick Ratio: 13.65%
Misc:
  • Average Volume: 597,248 shs.
  • Beta: 3.04
  • Short Ratio: 5.25
 

Frequently Asked Questions for Bio-Path Holdings (NASDAQ:BPTH)

What is Bio-Path Holdings' stock symbol?

Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."

How were Bio-Path Holdings' earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its earnings results on Thursday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. View Bio-Path Holdings' Earnings History.

When will Bio-Path Holdings make its next earnings announcement?

Bio-Path Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Bio-Path Holdings.

Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?

2 brokerages have issued twelve-month target prices for Bio-Path Holdings' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Bio-Path Holdings' stock price to reach $3.50 in the next year. View Analyst Ratings for Bio-Path Holdings.

Who are some of Bio-Path Holdings' key competitors?

Who are Bio-Path Holdings' key executives?

Bio-Path Holdings' management team includes the folowing people:

  • Peter Henry Nielsen, Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer
  • Ulrich W. Mueller Ph.D., Chief Operating Officer, Secretary
  • Douglas P. Morris, Director
  • Heath W. Cleaver CPA, Independent Director
  • Mark P. Colonnese, Independent Director

Who owns Bio-Path Holdings stock?

Bio-Path Holdings' stock is owned by a number of of institutional and retail investors. Top institutional investors include University of Texas Investment Managment Co. (4.01%), Vanguard Group Inc. (2.55%), Legal & General Group Plc (1.85%), HighTower Advisors LLC (1.27%) and Northern Trust Corp (0.32%). View Institutional Ownership Trends for Bio-Path Holdings.

Who sold Bio-Path Holdings stock? Who is selling Bio-Path Holdings stock?

Bio-Path Holdings' stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp and Vanguard Group Inc.. View Insider Buying and Selling for Bio-Path Holdings.

Who bought Bio-Path Holdings stock? Who is buying Bio-Path Holdings stock?

Bio-Path Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Legal & General Group Plc and HighTower Advisors LLC. View Insider Buying and Selling for Bio-Path Holdings.

How do I buy Bio-Path Holdings stock?

Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path Holdings' stock price today?

One share of Bio-Path Holdings stock can currently be purchased for approximately $0.35.


MarketBeat Community Rating for Bio-Path Holdings (NASDAQ BPTH)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Bio-Path Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (914.49% upside)

Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$2.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)
Earnings by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Earnings History by Quarter for Bio-Path Holdings (NASDAQ BPTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.02)N/AView Earnings Details
8/10/2017Q2 2017($0.02)($0.03)ViewListenView Earnings Details
5/11/2017Q1 2017($0.02)($0.01)ViewN/AView Earnings Details
3/15/201712/31/2016($0.03)($0.01)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.02)($0.02)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.02)($0.02)ViewN/AView Earnings Details
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.01)($0.02)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.02)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.01($0.02)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.01)($0.01)ViewN/AView Earnings Details
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details
4/2/2014$0.01$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.11 EPS

Dividends

Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Path Holdings (NASDAQ:BPTH)
Insider Ownership Percentage: 12.54%
Institutional Ownership Percentage: 15.16%
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Path Holdings (NASDAQ:BPTH)
Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
Source:
DateHeadline
seekingalpha.com logoBio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM
globenewswire.com logoBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM
finance.yahoo.com logoBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM
americanbankingnews.com logo-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM
americanbankingnews.com logoBio-Path Holdings, Inc. (BPTH) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - September 3 at 8:26 PM
americanbankingnews.com logoZacks: Analysts Expect Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - August 16 at 4:32 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Releases Earnings Results
www.americanbankingnews.com - August 11 at 2:34 PM
seekingalpha.com logoBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:50 PM
finance.yahoo.com logoBio-Path reports 2Q loss
finance.yahoo.com - August 10 at 5:50 PM
globenewswire.com logoBio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:58 PM
finance.yahoo.com logoBio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - August 3 at 6:08 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
finance.yahoo.com logoBio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent
finance.yahoo.com - July 31 at 4:44 PM
globenewswire.com logoBio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)
globenewswire.com - July 20 at 11:21 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 20 at 8:42 AM
streetinsider.com logoBio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.com
www.streetinsider.com - July 19 at 5:52 PM
nasdaq.com logoBio-Path Holdings Appoints Mark Colonnese to its Board of Directors - Nasdaq
www.nasdaq.com - July 17 at 5:04 PM
finance.yahoo.com logoBio-Path Holdings Appoints Mark Colonnese to its Board of Directors
finance.yahoo.com - July 17 at 12:23 PM
americanbankingnews.com logoBio-Path Holdings, Inc. (BPTH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - July 12 at 7:11 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Bio-Path Holdings, Inc. (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - July 5 at 7:45 AM
baystreet.ca logoStonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.ca
www.baystreet.ca - June 30 at 4:49 PM
finance.yahoo.com logoStonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
finance.yahoo.com - June 29 at 5:51 PM
americanbankingnews.com logo Brokerages Expect Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - June 9 at 7:40 AM
americanbankingnews.com logoReviewing Adamis Pharmaceuticals Corp (ADMP) & Bio-Path Holdings (BPTH)
www.americanbankingnews.com - June 3 at 10:40 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 13 at 12:02 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM
seekingalpha.com logoBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM
finance.yahoo.com logoBio-Path Holdings Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:36 PM
finance.yahoo.com logoBio-Path reports 1Q loss
finance.yahoo.com - May 11 at 4:36 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:16 AM
finance.yahoo.com logoBio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - May 4 at 4:07 PM
americanbankingnews.com logoPositive Media Coverage Likely to Affect Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - May 4 at 12:36 AM
americanbankingnews.com logoBio-Path Holdings (BPTH) Earns Daily Media Sentiment Score of 0.13
www.americanbankingnews.com - April 27 at 8:08 PM
americanbankingnews.com logoBio-Path Holdings (BPTH) Receives Daily Coverage Optimism Rating of 0.57
www.americanbankingnews.com - April 21 at 8:47 AM
finance.yahoo.com logoBio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher - Yahoo Finance
finance.yahoo.com - April 19 at 1:11 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Short Interest Up 2.3% in March
www.americanbankingnews.com - April 19 at 7:14 AM
americanbankingnews.com logoBio-Path Holdings (BPTH) Getting Very Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 8:56 AM
finance.yahoo.com logoBio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development
finance.yahoo.com - April 17 at 12:25 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Impact Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - April 15 at 10:29 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 7 at 10:44 PM
finance.yahoo.com logoBio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma
finance.yahoo.com - April 7 at 8:40 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Given a $2.00 Price Target at Maxim Group
www.americanbankingnews.com - April 5 at 6:45 PM
seekingalpha.com logoBio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM
americanbankingnews.com logoHC Wainwright Reiterates $5.00 Price Target for Bio-Path Holdings Inc (BPTH)
www.americanbankingnews.com - March 22 at 9:11 AM
americanbankingnews.com logoZacks Investment Research Upgrades Bio-Path Holdings Inc (BPTH) to "Buy"
www.americanbankingnews.com - March 20 at 9:49 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:43 AM
biz.yahoo.com logoBio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 15 at 9:21 PM
us.rd.yahoo.com logoBio-Path Holdings Reports Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 4:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 4:20 PM

Social

Chart

Bio-Path Holdings (BPTH) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff